A transformative moment in the global fight against obesity has emerged with the announcement of positive topline results ...

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...

Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount ...

A new daily weight loss pill could be available soon – and a recent trial has shown that people taking the drug can shed ...

Eli Lilly says their obesity pill led to more than 12% weight loss in closely watched late-stage trial, paving way for ...

While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...

It looks likely we'll see oral GLP-1 drugs on the market by next year, with pharmaceutical company Eli Lilly reporting ...

Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...

Trials of a daily obesity pill have shown it can help patients lose around 12% of their body weight over 72 weeks. The ...

An oral GLP-1 induced up to 12.4% weight loss at 72 weeks for adults with overweight or obesity, according to topline results ...